Pain Therapeutics, Inc. (NASDAQ:PTIE)

CAPS Rating: 2 out of 5

A biopharmaceutical company that develops novel drugs for pain management and oncology.

Results 1 - 20 of 29 : 1 2 Next »

Recs

0
Member Avatar SpartanMAC (< 20) Submitted: 4/14/2014 10:30:29 PM : Outperform Start Price: $5.17 PTIE Score: -33.97

Top 30 over $67M.

Recs

0
Member Avatar TrackMagicFormul (83.07) Submitted: 3/19/2014 2:38:05 PM : Outperform Start Price: $4.73 PTIE Score: -31.82

Investors should consider selling puts. You can achieve some very high annualized returns at strikes significantly below the current price. e.g.

Jul 14 $5.00 strike at 60¢ has 23% discount and 35% annualized return.

Recs

0
Member Avatar mchenrymike (< 20) Submitted: 1/8/2014 10:17:38 PM : Outperform Start Price: $4.93 PTIE Score: -29.88

A product that is most needed and looks to be a go in the next year

Recs

1
Member Avatar zzlangerhans (99.80) Submitted: 7/15/2013 7:42:56 PM : Underperform Start Price: $2.42 PTIE Score: -40.84

The Remoxy ship has taken on a lot of water and is listing dangerously to port. The share price will remain volatile in the near future as traders over-react to signals that purportedly indicate whether Pfizer will ultimately resubmit the NDA or kill the program. I lean towards kill, as Pain and Pfizer have suffered countless humiliating defeats on a drug that at first seemed like it would be an easy approval. The latest blow to Pain came in May when they received a letter from Pfizer stating that in the event upper management greenlighted a Remoxy resubmission, it wouldn't occur before 2015. If the next letter from Pfizer contains bad news, Pain's share price will likely drop below the cash value of 1.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 11/16/2012 9:45:14 AM : Outperform Start Price: $2.15 PTIE Score: +35.29

sounds a good biotech

Recs

0
Member Avatar beadnell (93.84) Submitted: 8/23/2011 4:32:17 AM : Outperform Start Price: $3.40 PTIE Score: -62.36

I'm dabbling in microcaps on CAPS

Recs

0

Recs

1
Member Avatar Simbalion200 (23.55) Submitted: 4/9/2010 10:54:24 AM : Outperform Start Price: $3.70 PTIE Score: -62.92

Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. As of December 31, 2009, the Company had four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a radio-labeled monoclonal antibody to treat metastatic melanoma. The Company's lead drug candidate is REMOXY, which is a painkiller. It has a collaboration agreement and a license agreement with King Pharmaceuticals, Inc. (King) to develop and commercialize REMOXY and other opioid painkillers. I am not excited about this company. Right now the company is not profitable. One year EPS growth is encouraging at 412.50%. The Return on Equity is a pitiful -3.23. The positive consideration is that there is always interest in effective pain medicines. Stock has been on a steady upward progression over the last year. However, this stock may be overbought, and I expect the stock price will begin to decline in price a bit. I do believe after a short correction this stock will outperform the market.

Recs

0
Member Avatar d0319a (< 20) Submitted: 9/22/2009 8:26:41 AM : Outperform Start Price: $3.20 PTIE Score: -65.54

pipeline and cash

Recs

0
Member Avatar FinanceGuy58 (59.83) Submitted: 9/17/2009 9:01:03 PM : Outperform Start Price: $3.18 PTIE Score: -64.74

A virtual pharma development company with several shots on goal. Remoxy already partnered with King Pharma. Abuse resistant forms of oxycontin should be a big hit. Great royalty rates. Another pic, Durect provides the drug delivery system for one of their pipeline products. PTIE holds tons of cash too - not going away. Very lean company, they outsource almost everything.

Recs

0
Member Avatar AAAAmanda (50.74) Submitted: 2/2/2009 2:37:12 PM : Outperform Start Price: $3.82 PTIE Score: -146.25

18.8486 at $210.00 or 11.14 per share. Sad. Very sad.

Recs

0
Member Avatar poppinkid (82.62) Submitted: 5/8/2008 9:14:41 PM : Outperform Start Price: $4.55 PTIE Score: -64.46

Doctor's would rather let a person in the ER suffer than get then hooked on oxy. An abuse resistant REMOXY is a big seller offering clear advantages over generics. This is a 500M+ product

Recs

0
Member Avatar onontrading (< 20) Submitted: 4/23/2008 11:33:50 PM : Outperform Start Price: $4.19 PTIE Score: -58.55

This stock has an average seasonality of 13% over the mid summer

Recs

0
Member Avatar pops83 (25.50) Submitted: 4/2/2008 4:12:47 AM : Outperform Start Price: $5.07 PTIE Score: -74.29

Purdue sure slipped that one in on King and PTIE. IS the increase in the buy back intended to further shore up the share price after the bomb dropped? The month of May will be interesting, to say the least. Still...................

Recs

1
Member Avatar AW2580 (48.55) Submitted: 11/1/2007 11:14:05 AM : Outperform Start Price: $6.38 PTIE Score: -76.23

Quarterly earnings keep improving and they have a non-addicting pain killer in ph III clinical trials.

Recs

0
Member Avatar tharlow (64.57) Submitted: 10/27/2007 12:31:05 AM : Outperform Start Price: $6.01 PTIE Score: -71.34

This could be massive.

Recs

0
Member Avatar razormd (77.93) Submitted: 8/22/2007 11:32:20 AM : Outperform Start Price: $5.67 PTIE Score: -75.35

Nothing much to add to what has already been noted by other CAPS players.

Recs

0
Member Avatar suave1007 (< 20) Submitted: 8/14/2007 6:41:26 PM : Outperform Start Price: $5.32 PTIE Score: -74.40

IN Phase 3 clinicals of Remoxy (an abuse resistant Oxycontin:$2+BLN annual sales) w/results by '07 yrend. Royalty rev's to ensue. $20mln stkbuy back. Mkt Cap of under $400 mln and financially strong with $200 mln cash burning $15 mln/yr. File for patents upon finishing Phase 3 clinicals trumping Purdue. Upon IND submission receive $150 mln milestone.
payment from King Rx in need of pipeline fill! Other compounds as well!

LARGE Short Interest=30 days to cover.

Recs

0
Member Avatar AtomicDoom (44.10) Submitted: 7/1/2007 10:18:10 PM : Outperform Start Price: $5.25 PTIE Score: -65.46

Fundamentals are awesome if they can keep it up. Highly undervalued.

Recs

4
Member Avatar NetscribeBiotech (95.06) Submitted: 5/30/2007 7:04:36 AM : Underperform Start Price: $4.99 PTIE Score: +61.65

The world pain management market is growing at a brisk pace and any company that is ready with a compound to tap this growing market has all reasons to cheer. Having said that Pain Therapeutics, which develops drugs catering to this segment as well as oncology, has lost its sheen in the recent weeks.

The company had three investigational drug candidates in phase III clinical program as on December 31, 2006 of which two where catering to the pain management segment. The company is also engaged in a strategic alliance with King pharmaceuticals for developing abuse resistant painkillers. The company does not have any product sales and the revenue that it has been generating comes mainly from milestone payment from King pharmaceuticals and interest income.

In March of this year the company made significant progress in its metastatic melanoma division as it received approval from the government of Israel to begin human testing for the new drug in this area. The same month also saw the company licensing a new technology to treat hemophilia, a rare blood disorder.

Nevertheless, the firm was pinning its hopes on the drugs Remoxy and Oxytrex, intended for the pain management segment and which was in phase III clinical trials. The scrip was inching forward in anticipation of the trial results of these two drugs, which was expected by mid 2007. The recent news that these results may not be available until end of the year and also that the company has not started registration on a phase III study for Oxytrex has put a spanner on this and the scrip began to dip.

There is an ambiguity surrounding the Remoxy and Oxytrex development timelines and with the absence of any other sufficient news item the performance of the company scrip is expected to be muted.

Results 1 - 20 of 29 : 1 2 Next »

Featured Broker Partners


Advertisement